Literature DB >> 11123240

Role of mitochondrial and sarcolemmal K(ATP) channels in ischemic preconditioning of the canine heart.

S Sanada1, M Kitakaze, H Asanuma, K Harada, H Ogita, K Node, S Takashima, Y Sakata, M Asakura, Y Shinozaki, H Mori, T Kuzuya, M Hori.   

Abstract

We tested whether mitochondrial or sarcolemmal ATP-sensitive K(+) (K(ATP)) channels play a key role in ischemic preconditioning (IP) in canine hearts. In open-chest beagle dogs, the left anterior descending artery was occluded four times for 5 min each with 5-min intervals of reperfusion (IP), occluded for 90 min, and reperfused for 6 h. IP as well as cromakalim and nicorandil (nonspecific K(ATP) channel openers) markedly limited infarct size (6.3 +/- 1.2, 8.9 +/- 1.9, and 7.2 +/- 1.6%, respectively) compared with the control group (40.9 +/- 4.1%). A selective mitochondrial K(ATP) channel blocker, 5-hydroxydecanoate, partially blunted the limitation of infarct size in the animals subjected to IP and those treated with cromakalim and nicorandil (21.6 +/- 3.8, 25.1 +/- 4.6, and 19.8 +/- 5.2%, respectively). A nonspecific K(ATP) channel blocker, glibenclamide, completely abolished the effect of IP (38.5 +/- 6.2%). Intracoronary or intravenous administration of a mitochondria-selective K(ATP) channel opener, diazoxide, at >100 micromol/l could only partially decrease infarct size (19.5 +/- 4.3 and 20.1 +/- 4.4%, respectively). In conclusion, mitochondrial and sarcolemmal K(ATP) channels independently play an important role in the limitation of infarct size by IP in the canine heart.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11123240     DOI: 10.1152/ajpheart.2001.280.1.H256

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  12 in total

Review 1.  Role of bradykinin in preconditioning and protection of the ischaemic myocardium.

Authors:  G F Baxter; Z Ebrahim
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

2.  Activation of ATP-dependent potassium channels is a trigger but not a mediator of ischaemic preconditioning in pigs.

Authors:  Rainer Schulz; Petra Gres; Gerd Heusch
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

3.  Cardioprotection by preconditioning: K(ATP) channels, metabolism, or both?

Authors:  N B Standen
Journal:  J Physiol       Date:  2002-08-01       Impact factor: 5.182

Review 4.  Multiplicity of effectors of the cardioprotective agent, diazoxide.

Authors:  William A Coetzee
Journal:  Pharmacol Ther       Date:  2013-06-19       Impact factor: 12.310

5.  Role of sarcolemmal K(ATP) channels in cardioprotection against ischemia/reperfusion injury in mice.

Authors:  Masashi Suzuki; Norihito Sasaki; Takashi Miki; Naoya Sakamoto; Yuki Ohmoto-Sekine; Masaji Tamagawa; Susumu Seino; Eduardo Marbán; Haruaki Nakaya
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

6.  An electrocardiographic sign of ischemic preconditioning.

Authors:  Loek P B Meijs; Loriano Galeotti; Esther P Pueyo; Daniel Romero; Robert B Jennings; Michael Ringborn; Stafford G Warren; Galen S Wagner; David G Strauss
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-04-28       Impact factor: 4.733

Review 7.  Nicorandil: a review of its use in the management of stable angina pectoris, including high-risk patients.

Authors:  Dene Simpson; Keri Wellington
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 8.  Evidence for mitochondrial K+ channels and their role in cardioprotection.

Authors:  Brian O'Rourke
Journal:  Circ Res       Date:  2004-03-05       Impact factor: 17.367

9.  Effect of metabolic inhibition on glimepiride block of native and cloned cardiac sarcolemmal K(ATP) channels.

Authors:  C L Lawrence; R D Rainbow; N W Davies; N B Standen
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

10.  Beta-oxidation of 5-hydroxydecanoate, a putative blocker of mitochondrial ATP-sensitive potassium channels.

Authors:  Peter J Hanley; K V Gopalan; Rachel A Lareau; D K Srivastava; Martin von Meltzer; Jürgen Daut
Journal:  J Physiol       Date:  2003-01-31       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.